Abstract
The choice of treatment in patients with hepatitis C virus infection should take into account the pharmacokinetic profile of drugs used in the treatment of this condition. Special considerations must also be given to patients with hepatic or renal impairment, and those who are co-infected with HIV.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
de Kanter CT, Drenth JP, Arends JE, et al. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2013;53(5):409–27.
Kohli A, Shaffer A, Sherman A, et al. Treatment of hepatitis C: a systematic review. JAMA. 2014;312(6):631–40.
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014;61(2):373–95.
Burger D, Back D, Buggisch P, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol. 2013;58(4):792–800.
Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut. 2012;61(Suppl 1):i47–58.
Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peinterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438–50.
Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13(7):597–605.
Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159(2):86–96.
Leutkemeyer AF, Havlir DV, Currier JS. CROI 2013: complications of HIV disease, viral hepatitis, and antiretroviral therapy. Top Antivir Med. 2013;21(2):62–74.
Karageorgopoulos DE, El-Sherif O, Bhagani S, et al. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis. 2014;27(1):36–45.
Sovaldi (sofosbuvir) tablets: US prescribing information. Foster City: Gilead Sciences, Inc.; 2013.
González-Peralta RP, Kelly DA, Haber B, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology. 2005;42(5):1010–8.
Disclosure
This article was adapted from Clinical Pharmacokinetics 2014;53(5):409–27 [1] by salaried/contracted employees of Adis/Springer. The preparation of these articles was not supported by any external funding. Some authors of the original article [1] received consulting fees, payments for lectures, or research grants or support from various pharmaceutical companies; these authors declare that these conflicts of interest did not influence the preparation of their article.
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Adis Medical Writers. Consider drug pharmacokinetics when selecting the most suitable treatments for hepatitis C infection. Drugs Ther Perspect 30, 427–431 (2014). https://doi.org/10.1007/s40267-014-0161-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-014-0161-1